Rivastigmine
Market, by Disease Indication (Alzheimer Disease and Parkinson’s Disease),
by Formulation ( Capsules and Transdermal Patches), by Distribution Channel
(Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies ), and by
Geography (North America, Asia Pacific, Europe, Latin America, Middle East, and
Africa) - Size, Share, Outlook, and Opportunity Analysis, 2018- 2026
Rivastigmine is a cholinesterase
enzyme inhibitor, which acts on butylcholinesterase and acetylcholinesterase.
It is a cholinergic agent that aids in the treatment of Alzheimer’s and
Parkinson’s disease. The drug can be administered orally or in transdermal
patches form, owing to its small molecular size.
Rivastigmine Market – Dynamics
Increasing geriatric population
is a major driver for growth of the rivastigmine market. According to The
Alzheimer Association, in 2018, the risk of suffering from dementia can
increase double fold above the age of 65 years in every 5 years. Moreover,
increasing prevalence of cardiovascular diseases worldwide also accounts for
the development of Alzheimer’s disease, thereby boosting demand for
rivastigmine. As per the National Center for Biotechnology Information
published in 2013, the incidence of cardiovascular diseases was around 22.5 per
1,000 person worldwide which in turn suggesting a risk of dementia.
* The sample copy includes:
Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report
Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2407
Diseases such as diabetes and
blood pressure can also increase the risk of dementia, which further boosts
demand for rivastigmine, thereby propelling the market growth.
Rivastigmine Market – Regional
Insights
The rivastigmine market is
segregated geographically into North America, Latin America, Asia Pacific,
Europe, Middle East, and Africa. North America accounted for the largest share
in the global rivastigmine market in 2017. This is owing to increasing
prevalence of chronic kidney disease in the region that may lead to dementia.
According to The American Kidney Fund, around 31 million people suffered from
chronic kidney disease in 2015. Europe accounted for the second largest share
in terms of revenue in the global rivastigmine market, in 2017 owing to
increasing geriatric population in the region. Geriatric population is more
prone to dementia. According to World Population Prospects (WPP), in 2017,
around 25% of the population in Europe was aged 60 years or above. According to
the Alzheimer’s Association, in 2017, there was significant prevalence of
vascular diseases in Latin America and Africa. Therefore, Latin America and
Africa are expected to witness significant growth in the global rivastigmine
market during the forecast period.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/rivastigmine-market-2407
Rivastigmine Market – Competitive
Landscape
Major players operating in the
global rivastigmine market include, Novartis Europharm Limited, Actavis Pharma,
Apotex Corporation, Aurobindo Pharm Ltd, Teva Pharmaceuticals Industries Ltd,
Dr. Reddy’s Laboratories, Macleods, and others. Key players in the market are
focused on product development and approvals in order to enhance their market
share. For instance, in 2007, U.S. FDA approved Exelon (Rivastigmine tartarate)
— developed by Novartis Europharm Limited for the treatment of Alzheimer's and
Parkinson's disease.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2407
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment